hemlibra
roche registration limited - emicizumab - Хемофилия А - Антихеморагични - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra могат да бъдат използвани във всички възрастови групи.
imipenem/cilastatin aptapharma 500 mg/500 mg powder for solution for infusion
500 mg/500 mg powder for solution for infusion
meropenem aptapharma 1000 mg powder for solution for injection/infusion
1000 mg powder for solution for injection/infusion
meropenem aptapharma 500 mg powder for solution for injection/infusion
500 mg powder for solution for injection/infusion
ceftazidim aptapharma 1 g powder for solution for injection/infusion
1 g powder for solution for injection/infusion
ceftriaxone aptapharma 1 g powder for solution for injection/infusion
1 g powder for solution for injection/infusion
ceftriaxone aptapharma 2 g powder for solution for injection/infusion
2 g powder for solution for injection/infusion
amoxicillin/clavulanic acid aptapharma 1000 mg/200 mg powder for solution for injection/infusion
1000 mg/200 mg powder for solution for injection/infusion
cefazolin aptapharma 1 g powder for solution for injection/infusion
1 g powder for solution for injection/infusion
ampicillin/sulbactam aptapharma 1 g/0,5 g powder for solution for injection/infusion
1 g/0,5 g powder for solution for injection/infusion